34.236.192.4
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup
Glaucoma

New Data Analyzes Safety, Efficacy of Bimatoprost Implant in Several Subgroups

Posted on May 15, 2020

Data analyzing safety and efficacy of bimatoprost implant for intracameral administration, was presented at the American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting.

The first presentation discussed data from 2 phase 3 studies evaluating bimatoprost compared with topical timolol in eyes with open-angle glaucoma (OAG) or ocular hypertension (OHT), which found bimatoprost was noninferior to timolol in patients with baseline IOP ≤25 mmHg and baseline IOP >25 mmHg. IOP was lowered on average by 9–10 mmHg in patients with baseline IOP >25 mmHg.

The next study presented found that bimatoprost effectively lowered intraocular pressure (IOP).in patients with prior selective laser trabeculoplasty and that after receiving 3 treatment, these patients were likely to remain treatment-free for 1 year.

The third paper presented evaluated the efficacy of bimatoprost in lowering IOP in patients with OAG and OHT who were previously treated with ≥2 topical IOP-lowering medications. Bimatoprost was found to lower IOP, with nearly half of patients having ≥30% reduction in IOP from baseline at 2, 6, and 12 weeks.

The final presentation highlighted data from a study that evaluated the safety of bimatoprost in patients with pseudophakic eyes, which may potentially affect the safety of intracameral implants due to larger anterior angles. Bimatoprost provided sustained IOP lowering in both phakic and pseudophakic eyes and had an acceptable safety profile in this population.

Reference

Weinreb, RN et al. Efficacy of bimatoprost SR in patients stratified By baseline IOP (≤25 or >25 mmHg):pPhase 3 study results at primary database lock. Presented at: American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting. May 16, 2020.

Brubaker, JW et al. Efficacy of bimatoprost sustained-release implant (bimatoprost SR) in eyes with prior SLT: phase 3 study results at primary database lock. Presented at: American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting. May 16, 2020.

Craven, ER et al. Results of phase 3 study of bimatoprost SR at primary database lock: IOP lowering in patients with prior topical therapy and responder rates. American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting. May 16, 2020.

Walters, TR et al. Efficacy and safety of bimatoprost SR (BimSR) in phakic and pseudophakic eyes: Phase 3 study results at primary database lock. American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting. May 16, 2020.

-Advertisement-
Related Articles
Compounded fixed-combination injection provides stable mydriasis during surgery
Aug 04, 2021
More research needed on link between strabismus and mental health disorders in kids
May 21, 2021
Patient demographics influence utilization of care for eye conditions
May 21, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-